Krystal Biotech, Inc.
KRYSNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $9.81B
- P/E (TTM)
- 40.64
- Forward P/E
- 24.36
- Dividend yield
- -
- 52-week range
- $183.03$382.54
- Volume (live)
- -
- Avg. volume (3M)
- 289.50K
Krystal Biotech (KRYS) Stock Price & Financial Analysis
Krystal Biotech Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $317.05 - $328.48 |
|---|---|
| 52-Week High | $382.54 |
| 52-Week Low | $183.03 |
| Open | $320.44 |
| Volume (last close) | 245.13K |
| Average Volume (3M) | 289.50K |
| Revenue (TTM) | 440.48M |
|---|---|
| Net Income (TTM) | 241.47M |
| Free Cash Flow (TTM) | 257.78M |
| EPS (TTM) | $7.99 |
| Profit Margin | 54.82% |
| Operating Margin | 44.93% |
| Return on Equity (ROE) | 17.77% |
| Debt to Equity | 0.01 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 9.81B |
|---|---|
| Shares Outstanding | 30.66M |
| P/E Ratio (TTM) | 40.64 |
| Forward P/E | 24.36 |
| Price to Sales (P/S) | 22.28 |
| Price to Book (P/B) | 7.22 |
| EV/EBITDA | 48.41 |
| 50-Day MA | $339.53 |
|---|---|
| 200-Day MA | $306.23 |
| 1-Year Change | +71.70% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Krystal Biotech at a Glance
As of the Oct 22, 2026 close, Krystal Biotech (KRYS) has a market capitalization of $9.81B. The stock trades at 40.6× trailing earnings, 24.4× forward earnings and 22.3× sales. Over the trailing twelve months it earned $241.47M on revenue of $440.48M (a 54.8% profit margin) and generated $257.78M of free cash flow. Revenue grew 22.6% year over year.
As of its latest reported balance sheet, it holds $427.74M in cash and securities against $8.85M of debt, a net cash position of $418.89M.
Krystal Biotech does not currently pay a dividend.
The share price is up 71.7% over the past year. At $320.13 (the Oct 22, 2026 close) it sits within its 52-week range of $183.03 to $382.54, above its 200-day moving average of $306.23.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $403.50, 26.0% above the Oct 22, 2026 close.
Frequently Asked Questions About Krystal Biotech
What is the current stock price for KRYS?
As of the Oct 22, 2026 close, KRYS stock trades at $320.13. The 52-week range is $183.03–$382.54, with a day range of $317.05–$328.48.
What is the P/E ratio for KRYS?
As of the Oct 22, 2026 close, Krystal Biotech's trailing twelve-month (TTM) P/E ratio is 40.6, meaning investors pay $40.6 for every $1 of annual earnings. The forward P/E is 24.4, reflecting analyst expectations for future earnings. Krystal Biotech operates in the Healthcare sector.
Does KRYS pay dividends?
Krystal Biotech does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for KRYS?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for KRYS is Buy. The average 12-month price target is $403.50, a 26.0% upside from the Oct 22, 2026 close of $320.13.
What is the market cap of KRYS?
As of the Oct 22, 2026 close, Krystal Biotech's market capitalization is $9.81B, classifying it as a mid-cap company. Krystal Biotech operates in the Healthcare sector within the Biotechnology industry.